Trial Profile

PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Infliximab (Primary)
Indications Ankylosing spondylitis; Crohn's disease; Inflammatory bowel diseases; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Focus Therapeutic Use
Acronyms PERFUSE
Sponsors Biogen

Most Recent Events

01 Apr 2023 Results (n=126 pediatric IBD patients cohort) assessing response to treatment and persistence on SB2 for up to 12 months in pediatric IBD patients published in the Journal of Pediatric Gastroenterology and Nutrition
17 Oct 2022 Status changed from active, no longer recruiting to completed.
06 Aug 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com